Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Risk Assessment of kINPen Plasma Treatment of Four Human Pancreatic Cancer Cell Lines with Respect to Metastasis.

Bekeschus S, Freund E, Spadola C, Privat-Maldonado A, Hackbarth C, Bogaerts A, Schmidt A, Wende K, Weltmann KD, von Woedtke T, Heidecke CD, Partecke LI, Käding A.

Cancers (Basel). 2019 Aug 23;11(9). pii: E1237. doi: 10.3390/cancers11091237.

2.

Murine Distal Colostomy, A Novel Model of Diversion Colitis in C57BL/6 Mice.

Kleinwort A, Döring P, Hackbarth C, Patrzyk M, Heidecke CD, Schulze T.

J Vis Exp. 2018 Jul 12;(137). doi: 10.3791/57616.

PMID:
30059029
3.

Cold Physical Plasma-Treated Buffered Saline Solution as Effective Agent Against Pancreatic Cancer Cells.

Bekeschus S, Käding A, Schröder T, Wende K, Hackbarth C, Liedtke KR, van der Linde J, von Woedtke T, Heidecke CD, Partecke LI.

Anticancer Agents Med Chem. 2018;18(6):824-831. doi: 10.2174/1871520618666180507130243.

PMID:
29732979
4.

Deviation of the Fecal Stream in Colonic Bowel Segments Results in Increased Numbers of Isolated Lymphoid Follicles in the Submucosal Compartment in a Novel Murine Model of Diversion Colitis.

Kleinwort A, Döring P, Hackbarth C, Heidecke CD, Schulze T.

Biomed Res Int. 2017;2017:5265969. doi: 10.1155/2017/5265969. Epub 2017 Aug 13.

5.

Non-thermal plasma-treated solution demonstrates antitumor activity against pancreatic cancer cells in vitro and in vivo.

Liedtke KR, Bekeschus S, Kaeding A, Hackbarth C, Kuehn JP, Heidecke CD, von Bernstorff W, von Woedtke T, Partecke LI.

Sci Rep. 2017 Aug 16;7(1):8319. doi: 10.1038/s41598-017-08560-3.

6.

Further insights into the anti-PF4/heparin IgM immune response.

Krauel K, Schulze A, Jouni R, Hackbarth C, Hietkamp B, Selleng S, Koster A, Jensch I, van der Linde J, Schwertz H, Bakchoul T, Hundt M, Greinacher A.

Thromb Haemost. 2016 Apr;115(4):752-61. doi: 10.1160/TH15-08-0654. Epub 2015 Oct 15.

PMID:
26467272
7.

Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies.

Krauel K, Hackbarth C, Fürll B, Greinacher A.

Blood. 2012 Feb 2;119(5):1248-55. doi: 10.1182/blood-2011-05-353391. Epub 2011 Nov 2.

PMID:
22049520
8.
9.

Synthesis and structure-activity studies of antibacterial oxazolidinones containing dihydrothiopyran or dihydrothiazine C-rings.

Renslo AR, Luehr GW, Lam S, Westlund NE, Gómez M, Hackbarth CJ, Patel DV, Gordeev MF.

Bioorg Med Chem Lett. 2006 Jul 1;16(13):3475-8. Epub 2006 Apr 27.

PMID:
16644216
10.

Conformational constraint in oxazolidinone antibacterials. Synthesis and structure-activity studies of (azabicyclo[3.1.0]hexylphenyl)oxazolidinones.

Renslo AR, Jaishankar P, Venkatachalam R, Hackbarth C, Lopez S, Patel DV, Gordeev MF.

J Med Chem. 2005 Jul 28;48(15):5009-24.

PMID:
16033280
11.

In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.

Lopez S, Hackbarth C, Romanò G, Trias J, Jabes D, Goldstein BP.

J Antimicrob Chemother. 2005 Mar;55 Suppl 2:ii21-4.

PMID:
15750033
12.

Conformationally restricted analogs of deoxynegamycin.

Raju B, Anandan S, Gu S, Herradura P, O'Dowd H, Kim B, Gomez M, Hackbarth C, Wu C, Wang W, Yuan Z, White R, Trias J, Patel DV.

Bioorg Med Chem Lett. 2004 Jun 21;14(12):3103-7.

PMID:
15149653
13.

Peptide deformylase inhibitors as antibacterial agents: identification of VRC3375, a proline-3-alkylsuccinyl hydroxamate derivative, by using an integrated combinatorial and medicinal chemistry approach.

Chen D, Hackbarth C, Ni ZJ, Wu C, Wang W, Jain R, He Y, Bracken K, Weidmann B, Patel DV, Trias J, White RJ, Yuan Z.

Antimicrob Agents Chemother. 2004 Jan;48(1):250-61.

14.

Alpha-substituted hydroxamic acids as novel bacterial deformylase inhibitor-based antibacterial agents.

Jain R, Sundram A, Lopez S, Neckermann G, Wu C, Hackbarth C, Chen D, Wang W, Ryder NS, Weidmann B, Patel D, Trias J, White R, Yuan Z.

Bioorg Med Chem Lett. 2003 Dec 1;13(23):4223-8. Erratum in: Bioorg Med Chem Lett. 2004 May 3;14(9):2373-4.

PMID:
14623006
15.

Novel oxazolidinone-quinolone hybrid antimicrobials.

Gordeev MF, Hackbarth C, Barbachyn MR, Banitt LS, Gage JR, Luehr GW, Gomez M, Trias J, Morin SE, Zurenko GE, Parker CN, Evans JM, White RJ, Patel DV.

Bioorg Med Chem Lett. 2003 Dec 1;13(23):4213-6.

PMID:
14623004
16.

New antibacterial tetrahydro-4(2H)-thiopyran and thiomorpholine S-oxide and S,S-dioxide phenyloxazolidinones.

Singh U, Raju B, Lam S, Zhou J, Gadwood RC, Ford CW, Zurenko GE, Schaadt RD, Morin SE, Adams WJ, Friis JM, Courtney M, Palandra J, Hackbarth CJ, Lopez S, Wu C, Mortell KH, Trias J, Yuan Z, Patel DV, Gordeev MF.

Bioorg Med Chem Lett. 2003 Dec 1;13(23):4209-12.

PMID:
14623003
17.

Combinatorial modification of natural products: synthesis and in vitro analysis of derivatives of thiazole peptide antibiotic GE2270 A: A-ring modifications.

Clough J, Chen S, Gordon EM, Hackbarth C, Lam S, Trias J, White RJ, Candiani G, Donadio S, Romanò G, Ciabatti R, Jacobs JW.

Bioorg Med Chem Lett. 2003 Oct 20;13(20):3409-14.

PMID:
14505638
18.

N- and C-terminal modifications of negamycin.

Raju B, Mortell K, Anandan S, O'Dowd H, Gao H, Gomez M, Hackbarth C, Wu C, Wang W, Yuan Z, White R, Trias J, Patel DV.

Bioorg Med Chem Lett. 2003 Jul 21;13(14):2413-8.

PMID:
12824046
19.

N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity.

Hackbarth CJ, Chen DZ, Lewis JG, Clark K, Mangold JB, Cramer JA, Margolis PS, Wang W, Koehn J, Wu C, Lopez S, Withers G 3rd, Gu H, Dunn E, Kulathila R, Pan SH, Porter WL, Jacobs J, Trias J, Patel DV, Weidmann B, White RJ, Yuan Z.

Antimicrob Agents Chemother. 2002 Sep;46(9):2752-64.

20.

Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB.

Margolis P, Hackbarth C, Lopez S, Maniar M, Wang W, Yuan Z, White R, Trias J.

Antimicrob Agents Chemother. 2001 Sep;45(9):2432-5.

21.

A proteolytic transmembrane signaling pathway and resistance to beta-lactams in staphylococci.

Zhang HZ, Hackbarth CJ, Chansky KM, Chambers HF.

Science. 2001 Mar 9;291(5510):1962-5.

22.

Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene.

Margolis PS, Hackbarth CJ, Young DC, Wang W, Chen D, Yuan Z, White R, Trias J.

Antimicrob Agents Chemother. 2000 Jul;44(7):1825-31.

23.

Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor.

Chen DZ, Patel DV, Hackbarth CJ, Wang W, Dreyer G, Young DC, Margolis PS, Wu C, Ni ZJ, Trias J, White RJ, Yuan Z.

Biochemistry. 2000 Feb 15;39(6):1256-62.

PMID:
10684604
24.
26.

Cloning and sequence analysis of a class A beta-lactamase from Mycobacterium tuberculosis H37Ra.

Hackbarth CJ, Unsal I, Chambers HF.

Antimicrob Agents Chemother. 1997 May;41(5):1182-5.

27.

Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.

Kocagöz T, Hackbarth CJ, Unsal I, Rosenberg EY, Nikaido H, Chambers HF.

Antimicrob Agents Chemother. 1996 Aug;40(8):1768-74.

28.

Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis?

Chambers HF, Moreau D, Yajko D, Miick C, Wagner C, Hackbarth C, Kocagöz S, Rosenberg E, Hadley WK, Nikaido H.

Antimicrob Agents Chemother. 1995 Dec;39(12):2620-4.

29.

Point mutations in Staphylococcus aureus PBP 2 gene affect penicillin-binding kinetics and are associated with resistance.

Hackbarth CJ, Kocagoz T, Kocagoz S, Chambers HF.

Antimicrob Agents Chemother. 1995 Jan;39(1):103-6.

30.
31.

Kinetics of penicillin binding to penicillin-binding proteins of Staphylococcus aureus.

Chambers HF, Sachdeva MJ, Hackbarth CJ.

Biochem J. 1994 Jul 1;301 ( Pt 1):139-44.

32.
33.

The pharmacokinetics of teicoplanin in varying degrees of renal function.

Lam YW, Kapusnik-Uner JE, Sachdeva M, Hackbarth C, Gambertoglio JG, Sande MA.

Clin Pharmacol Ther. 1990 May;47(5):655-61.

PMID:
2140543
34.

Methicillin-resistant staphylococci: detection methods and treatment of infections.

Hackbarth CJ, Chambers HF.

Antimicrob Agents Chemother. 1989 Jul;33(7):995-9. Review. No abstract available.

35.

Methicillin-resistant staphylococci: genetics and mechanisms of resistance.

Hackbarth CJ, Chambers HF.

Antimicrob Agents Chemother. 1989 Jul;33(7):991-4. Review. No abstract available.

36.

Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia.

Kapusnik JE, Hackbarth CJ, Chambers HF, Carpenter T, Sande MA.

J Infect Dis. 1988 Jul;158(1):7-12. Erratum in: J Infect Dis 1988 Oct;158(4):911.

PMID:
3392422
38.

The influence of fever on the development of experimental Streptococcus pneumoniae meningitis.

Sande MA, Sande ER, Woolwine JD, Hackbarth CJ, Small PM.

J Infect Dis. 1987 Nov;156(5):849-50. No abstract available.

PMID:
3655405
39.
40.

Antibiotic therapy, endotoxin concentration in cerebrospinal fluid, and brain edema in experimental Escherichia coli meningitis in rabbits.

Täuber MG, Shibl AM, Hackbarth CJ, Larrick JW, Sande MA.

J Infect Dis. 1987 Sep;156(3):456-62.

PMID:
3302052
41.

Ciprofloxacin in experimental Pseudomonas aeruginosa meningitis in rabbits.

Hackbarth CJ, Chambers HF, Stella F, Shibl AM, Sande MA.

J Antimicrob Chemother. 1986 Nov;18 Suppl D:65-9.

PMID:
3100492
42.

Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus.

Carpenter TC, Hackbarth CJ, Chambers HF, Sande MA.

Antimicrob Agents Chemother. 1986 Sep;30(3):382-4.

43.

Influence of body temperature on bacterial growth rates in experimental pneumococcal meningitis in rabbits.

Small PM, Täuber MG, Hackbarth CJ, Sande MA.

Infect Immun. 1986 May;52(2):484-7.

44.

Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus.

Hackbarth CJ, Chambers HF, Sande MA.

Antimicrob Agents Chemother. 1986 Apr;29(4):611-3.

45.

Evaluation of pefloxacin in experimental Escherichia coli meningitis.

Shibl AM, Hackbarth CJ, Sande MA.

Antimicrob Agents Chemother. 1986 Mar;29(3):409-11.

46.

Serum bactericidal titer as a predictor of outcome in endocarditis.

Hackbarth CJ, Chambers HF, Sande MA.

Eur J Clin Microbiol. 1986 Feb;5(1):93-7.

PMID:
2938947
47.

Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus.

Sullam PM, Täuber MG, Hackbarth CJ, Chambers HF, Scott KG, Sande MA.

Antimicrob Agents Chemother. 1985 May;27(5):685-7.

48.

Activities of pefloxacin and ciprofloxacin in experimentally induced Pseudomonas pneumonia in neutropenic guinea pigs.

Gordin FM, Hackbarth CJ, Scott KG, Sande MA.

Antimicrob Agents Chemother. 1985 Apr;27(4):452-4.

49.

Influence of the developmental state of valvular lesions on the antimicrobial activity of cefotaxime in experimental enterococcal infections.

Sullam PM, Drake TA, Täuber MG, Hackbarth CJ, Sande MA.

Antimicrob Agents Chemother. 1985 Mar;27(3):320-3.

50.

New cephalosporins cefotaxime, cefpimizole, BMY 28142, and HR 810 in experimental pneumococcal meningitis in rabbits.

Täuber MG, Hackbarth CJ, Scott KG, Rusnak MG, Sande MA.

Antimicrob Agents Chemother. 1985 Mar;27(3):340-2.

Supplemental Content

Loading ...
Support Center